Compare MWH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWH | EWTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.3B |
| IPO Year | 2026 | 2021 |
| Metric | MWH | EWTX |
|---|---|---|
| Price | $23.64 | $37.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $43.00 | ★ $52.62 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 08-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.24 | N/A |
| Revenue Next Year | $15.21 | N/A |
| P/E Ratio | $217.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.12 | $14.68 |
| 52 Week High | $48.40 | $48.51 |
| Indicator | MWH | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 37.89 |
| Support Level | $23.71 | $30.66 |
| Resistance Level | $27.27 | $41.22 |
| Average True Range (ATR) | 1.13 | 1.64 |
| MACD | -0.05 | -0.25 |
| Stochastic Oscillator | 23.06 | 28.73 |
SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.